Compare BMRN & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRN | PPC |
|---|---|---|
| Founded | 1996 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.9B |
| IPO Year | 1999 | 1987 |
| Metric | BMRN | PPC |
|---|---|---|
| Price | $53.19 | $39.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 2 |
| Target Price | ★ $88.42 | $47.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 10-27-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 21.14% |
| EPS Growth | ★ 59.53 | 24.34 |
| EPS | 2.68 | ★ 5.16 |
| Revenue | $3,094,001,000.00 | ★ $18,351,780,000.00 |
| Revenue This Year | $13.39 | $3.95 |
| Revenue Next Year | $7.57 | $0.51 |
| P/E Ratio | $19.92 | ★ $7.70 |
| Revenue Growth | ★ 12.39 | 1.76 |
| 52 Week Low | $50.76 | $35.73 |
| 52 Week High | $73.51 | $57.16 |
| Indicator | BMRN | PPC |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 64.46 |
| Support Level | $53.03 | $37.17 |
| Resistance Level | $54.66 | $40.11 |
| Average True Range (ATR) | 1.45 | 0.82 |
| MACD | -0.11 | 0.30 |
| Stochastic Oscillator | 31.61 | 88.33 |
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed that JBS' offer undervalued Pilgrim's Pride.